期刊文献+

183例三阴性乳腺癌临床病理特征及生存分析 被引量:18

Clinicopathologic characteristics and survival analysis of 183 cases of triple negative breast cancer
原文传递
导出
摘要 目的研究三阴性乳腺癌的临床病理特征和预后。方法回顾性分析南京医科大学第一附属医院2003年1月至2009年12月收治的1042例原发乳腺癌患者的临床资料。所有患者通过免疫组化分为3组:ERBB2+,HR+/ERBB-和三阴性乳腺癌。结果183例为三阴性乳腺癌。三阴性乳腺癌患者其肿块直径超过2cm的比例和组织学分级三级发生率比ERBB2+和HR+/ERBB2-患者高(P〈0.01)。而ERBB2+患者的P53阳性率比三阴性乳腺癌患者和HR+/ERBB2-患者高(P〈0.01)。HR+/ERBB2-患者与ERBB2+患者、三阴性乳腺癌患者相比骨转移比例更高(P=0.006)。3组患者间内脏远处转移差异无统计学意义。随访期间,3组5年无复发生存率差异有统计学意义(P=0.029),ERBB2+患者最低,为80.3%。结论本组三阴性乳腺癌患者肿块直径超过2cm比例较高,组织学分级三级发生率较高,但其5年无复发生存率高于ERBB2+患者。 Objective To investigate the clinicopathologic characteristics and prognosis of triple negative breast cancer patients. Methods A retrospective analysis was performed for 1042 primary breast cancer patients admitted in the First Affiliated Hospital of Nanjing Medical University from January 2003 to December 2009. All breast cancer patients were categorized into three subgroups by immunohistochemistry : ERBB2 +, HR +/ERBB2 - and triple negative. Results Of 1042 breast cancer patients recruited, 183 patients were in triple negative group. The rate of larger tumors ( greater than 2 cm in diameter) and grade HI in triple negative patients was higher than that in ERBB2 + and HR +/ERBB2 - patients (P 〈 0.01 ). The positive rate of p53 status in ERBB2 + patients was higher than that in triple negative and HR +/ ERBB2 - patients (P 〈 0. 01 ). No significant differences were observed in other clinical variables. In survival analysis, more bone metastases were observed in HR +/ERBB2 - patients than in ERBB2 + and triple negative patients ( P = 0. 006). However, no significant difference was observed in visceral metastases among the subgroups. There were significantly different recurrence-free survivals (RFS) among the three subgroups throughout the follow-up period (P = 0. 029), the 5-year RFS of ERBB2 + was 80. 3%, which was the worst in three groups. Conclusions Triple negative patients had higher rate of larger tumors (greater than 2 cm in diameter) and grade HI than that in ERBB2 + and HR +/ERBB2 - patients,while its 5-year RFS was higher than ERBB2 + patients.
出处 《中华普通外科杂志》 CSCD 北大核心 2012年第3期230-233,共4页 Chinese Journal of General Surgery
基金 国家自然科学基金资助项目(30740076) 江苏省六大人才高峰基金资助项目(06-B-069) 江苏省科教兴卫工程基金资助项目(RC2007054) 江苏省自然科学基金资助项目(BK2008476,BK2009438,BK2010581)
关键词 乳腺肿瘤 受体 雌激素 基因 ERBB-2 病理学 临床 Breast neoplasms Receptors,estrogen Gene,erbB-2 Pathology,clinical
  • 相关文献

参考文献10

  • 1Scrlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci, 2001, 98: 10869- 10874.
  • 2Dent R, Trudean M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res ,2007,13:4429-4434.
  • 3Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006,295:2492-2502.
  • 4Wu Y, Mohamed H, Chillar R, et al. Clinical significance of Akt and HER2/neu overexpression in African American and Latina women with breast cancer: a retrospective cohort study. Breast Cancer Res, 2008, 10 :R3.
  • 5Abd El-Rehim DM, Ball G, Pinder SE, et al. High-threughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer, 2005,116:340-350.
  • 6Kurebayashi J, Moriya T, Ishida T, et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast ,2007,16 : S72-77.
  • 7Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oneology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007, 25:5287- 5312.
  • 8Yin WJ, Lu JS, Di GH, et al. Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat, 2009, 115:325-333.
  • 9Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early- stage breast cancer. J Clin Oncol, 2006, 24:5652-5657.
  • 10Gori S, Rimoudini S, De Angelis V, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oneologist ,2007,12:766-773.

同被引文献115

  • 1须捷平,徐曙光,张云,俞羚,吴连明,殷志强,曹晖.三阴性乳腺癌的临床病理特征和预后影响因素分析[J].上海交通大学学报(医学版),2011,31(5):637-641. 被引量:18
  • 2陈曦,吴晶晶,张妍,欧阳学农,李捷.三阴性乳腺癌临床病理特征及与药物敏感度蛋白的相关性[J].肿瘤防治研究,2014,41(5):439-442. 被引量:15
  • 3<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 4Dent R, Trudean M, Pritchard KI, et al. Triple negative breast canc- er:Clinical features and patterns of recurrence [ J]. Clin Cancer Res,2007,13:4429 - 4434.
  • 5Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical impli-cations [ J ]. Proc Natl Acad Sci, 1998,19 : 10869 - 10874.
  • 6Voduc D, Nielsen TO. Basal and triple - negative breast cancers: Impact on clinical decision - making and novel therapeutic options [ J]. Clin Breast Cancer,2008,8 ( S. 014) :S171 - S178.
  • 7Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets [ J]. Proc Natl Acad Sci USA,2003,100(14) :8418 -8423.
  • 8Wang Y, Yin Q, Yu Q, et al. A retrospective study of breast cancer subtypes :the risk of relapse and the relations with treatments[ J]. Breast Cancer Res Treat,2011,130 ( 2 ) :489 - 498.
  • 9Rakha EA, E1 - Sayed ME, Green AR, et al. Prognostic markers in triple - negative breast cancer[ J]. Cancer,2007,109:25 - 32.
  • 10Hernandez - Aya LF, Chavez - Macgregor M, Lei X, et al. Nodal status and clinical outcomes in a large cohort of patients with triple - negative breast cancer[ J ]. J Clin Oncol, 2011,29 ( 19 ) : 2628 - 2634.

引证文献18

二级引证文献75

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部